Results from Part-1 of ON-5001: A Multi-center, Dose Escalation and Dose Finding Phase 1 Trial of ONM-501, a Dual-Acting STING Agonist

ONM-501

Oct 29

Brad Good has been an endorsed Squarespace Expert since the beginning and has been working on the platform since 2008. He has helped hundreds of Squarespace customers with their websites.

http://www.bradgood.net

Results from Part-1 of ON-5001: A Multi-center, Dose Escalation and Dose Finding Phase 1 Trial of ONM-501, a Dual-Acting STING Agonist

ONM-421, a pH-responsive Polymer-Drug Conjugate Nanoparticle, Delivers MMAE to Solid Tumors and Shows Antigen-Independent Antitumor Efficacy in Mice

A Phase 1 Dose-escalation and Expansion Study of an Intratumorally Administered Dual STING Agonist (ONM-501) Alone and in Combination with Cemiplimab